

compounds were fully spectroscopically characterized by ¹H-NMR, ¹³C-NMR, and HRMS, observing the following signs:

In ¹H-NMR, compound (1) presented an aromatic signal from the phenyl group with a δ ranging from 7.33 to 7.08 ppm, integrating five hydrogens. Additionally, a signal integrating for two hydrogens with a δ ranging from 3.45 to 3.39 ppm from the methylene part of the Ph-CH₂-N portion was observed, along with a signal integrating for one hydrogen with a δ ranging from 2.48 to 2.35 ppm. Compound (2) presented a signal integrating for one hydrogen at δ 8.70 ppm from the N-H amide, and an aromatic signal from quinoline with a δ ranging from 8.37 to 7.36 ppm. Compound (3) presented an aromatic signal at δ 6.58 ppm, integrating for two hydrogens from the 1,2,3,4-tetrahydroisoquinoline phenyl group, and a signal at δ 3.80 ppm, integrating for six hydrogens from the 1,2,3,4-tetrahydroisoquinoline methoxy group. Compound (4) presented an aromatic signal from the phenyl group with a δ ranging from 7.33 to 7.08 ppm, integrating five hydrogens. Additionally, this compound showed signals with δ ranging from 3.87 to 3.54 ppm, integrating for one hydrogen from the methylene of the alkyl chain of the piperidine group. Finally, compound (5) presented an aromatic signal with a δ ranging from 8.27 to 7.87 ppm, integrating nine hydrogens from pyrene. Additionally, a signal integrating two hydrogens at δ 4.16 ppm from the methylene group bonded to the oxygen of the ester group was observed. On the other hand, in ¹³C-NMR, compounds (1-5) exhibited a signal in the range of δ 173.56 to 170.98 ppm, which corresponds to the carbonyl carbon of the amide or ester.

For high-resolution mass spectroscopy, molar masses found by this technique of all compounds were compared with that calculated theoretically.

Chemistry

1-(benzyl-4-piperidinyl)methyl 5-(1,2-dithiolan-3-yl)pentanoate (1)

Compound (1) was prepared as described in procedures (A). Obtained as a dark yellow oil, yield 73.5%. (C₂₁H₃₁NO₂S₂): ¹H-NMR (400 MHz, CDCl₃) δ 7.33 – 7.08 (m, 5H), 3.97 – 3.83 (m, 2H), 3.49 – 3.39 (m, 2H), 3.19 – 3.04 (m, 1H), 2.90 – 2.80 (m, 2H), 2.72 (s, 1H), 2.48 – 2.35 (m, 1H), 2.31 – 2.21 (m, 2H), 1.98 – 1.85 (m, 3H), 1.66 – 1.57 (m, 6H), 1.47 – 1.38 (m, 2H), 1.31 – 1.16 (m, 3H). ¹³C-NMR (101 MHz, CDCl₃) δ 173.55, 138.43, 129.17, 128.17, 126.95, 68.79, 63.40, 56.34, 53.22, 40.22, 38.49, 35.34, 34.61, 34.08, 29.71, 28.95, 28.78, 24.74. HRMS m/z calcd. for C₂₁H₃₁NO₂S₂ (M+H), 394.1869; found, 394.1877.

4-(1,2-dithiolan-3-yl)-N-(quinolin-6-yl)butanamide (2)

Compound (2) was prepared as described in procedures (B). Obtained as a dark yellow oil, yield 45.1%. (C₁₇H₂₀N₂OS₂): ¹H-NMR (400 MHz, CDCl₃) δ 8.70 (s, 1H), 8.37 (s, 1H), 8.31 (s, 1H), 7.97 (d, J = 8.4 Hz, 1H), 7.89 (d, J = 9.0 Hz, 1H), 7.50 (d, J = 9.0 Hz, 1H), 7.26 (dd, J = 8.6, 4.2 Hz, 1H), 3.42 (m, 1H), 3.01 (m, 2H), 2.40 – 2.22 (m, 4H), 1.80 – 1.62 (m, 4H), 1.38 (m, 2H), 1.18 – 1.02 (m, 2H), 0.73 (m, 2H). ¹³C-NMR (101 MHz, CDCl₃) δ 171.82, 149.22, 145.32, 136.20, 136.02, 129.83, 128.89, 123.41, 121.67, 116.18, 56.39, 40.24, 38.48, 34.67, 34.62, 28.88, 25.26. HRMS m/z calcd. for C₁₇H₂₀N₂OS₂ (M+H), 333.1090; found, 333.1099.

1-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-4-(1,2-dithiolan-3-yl)butanone (3)

Compound (3) was prepared as described in procedures (C). Obtained as a dark yellow oil, yield 81.2%. (C₁₉H₂₇NO₃S₂): ¹H-NMR (400 MHz, CDCl₃) δ 6.58 (s, 2H), 4.64 – 4.47 (m, 2H), 3.80 (s, 6H), 3.64 – 3.49 (m, 2H), 3.24 – 3.03 (m, 1H), 2.82 – 2.69 (m, 4H), 2.39 (m, 3H), 1.89 (m, 1H), 1.46 (m, 4H), 1.18 (m, 1H), 0.83 (m, 2H). ¹³C-NMR (101 MHz, CDCl₃) δ 171.58, 147.90, 147.68, 126.99, 125.83, 111.29, 109.45, 56.46, 56.09, 55.99, 43.90, 43.37, 40.25, 38.50, 34.78, 33.31, 29.11, 28.09, 24.96. HRMS m/z calcd. for C₁₉H₂₇NO₃S₂ (M+H), 382.1505; found, 382.1506.

1-(4-benzyl-1-piperidinyl)-5-(1,2-dithiolan-3-yl)pentanone (4)

Compound (4) was prepared as described in procedures (D). Obtained as a dark yellow oil, yield 54.2%. (C₂₀H₂₉NOS₂): ¹H-NMR (400 MHz, CDCl₃) δ 7.35 – 7.02 (m, 5H), 3.94 – 3.83 (m, 1H), 3.77 (d, J = 13.6 Hz, 1H), 3.71 – 3.60 (m, 1H), 3.60 – 3.49 (m, 1H), 3.19 – 3.02 (m, 2H), 2.81 – 2.67 (m, 1H), 2.55 – 2.47 (m, 2H), 2.47 – 2.34 (m, 3H), 2.04 – 1.85 (m, 4H), 1.73 – 1.63 (m, 2H), 1.48 – 1.41 (m, 4H), 1.27 – 1.07 (m, 1H), 0.88 – 0.68 (m, 1H). ¹³C-NMR (101 MHz, CDCl₃) δ 170.98, 139.95, 129.08, 128.30, 126.05, 56.42, 42.98, 40.25, 38.50, 38.27, 34.70, 32.77, 30.96, 28.88, 26.34, 25.50, 25.35, 24.74. HRMS m/z calcd. for C₂₀H₂₉NOS₂ (M+H), 364.1763; found, 364.1772.

4-(pyren-1-yl)butyl 5-(1,2-dithiolan-3-yl)pentanoate (5)

Compound (5) was prepared as described in procedures (E). Obtained as a dark yellow oil, yield 64.0%. (C₂₈H₃₀O₂S₂): ¹H-NMR (400 MHz, CDCl₃) δ 8.27 (dd, J = 9.2, 1.8 Hz, 1H), 8.17 (dd, J = 7.8, 4.5 Hz, 2H), 8.15 – 8.07 (m, 2H), 8.07 – 7.94 (m, 3H), 7.87 (dd, J = 7.9, 1.7 Hz, 1H), 4.16 (m, 2H), 3.51 (m, 1H), 3.39 (t, J = 7.7 Hz, 2H), 3.18 – 3.01 (m, 2H), 2.45 – 2.23 (m, 3H), 1.95 (m, 1H), 1.84 – 1.79 (m, 2H), 1.71 – 1.54 (m, 6H), 1.49 – 1.37 (m, 2H). ¹³C-NMR (101 MHz, CDCl₃) δ 173.56, 136.34, 131.45, 130.90, 129.89, 128.63, 127.52, 127.30, 127.25, 126.66, 125.85, 125.13, 125.04, 124.93, 124.83, 124.74, 123.30, 64.19, 56.32, 40.17, 38.45, 34.58, 34.12, 33.06, 28.75, 28.68, 28.15, 24.73. HRMS m/z calcd. for C₂₈H₃₀O₂S₂ (M-H), 461.1603; found, 461.1632.

CONCLUSIONS

Considering the high sensitivity of ALA to the reaction medium, Steglich esterification is a good option to be used to prepare ALA derivatives. All compounds were obtained and fully characterized by ¹H-NMR, ¹³C-NMR, and HRMS.

ACKNOWLEDGMENTS

This work was supported by FONDECYT-Iniciación 11220164.

INTEREST CONFLICT

We declare no interest conflict in this work.

REFERENCES

- C. Bellini, F. Mancin, E. Papini, R. Tavano, *Antioxidants*. **13** (2024).
- A.K. Tripathi, A.K. Ray, S.K. Mishra, S.M. Bishen, H. Mishra, A. Khurana, *Rev. Bras. Farmacogn.* **33** (2023).
- A. Gruzman, A. Hidmi, J. Katzhendler, A. Haj-Yehie, S. Sasson, *Bioorg. Med. Chem.* **12** (2004).
- M. Turkowicz, I. Jastrzebska, M. Hryniewicka, U. Kotowska, D. Gudalewska, J. Karpińska, *Food Chem.* **309** (2020).
- V.E. Kagan, E.A. Serbinova, G.M. Koynova, S.A. Kitanova, V.A. Tyurin, T.S. Stoytchev, P.J. Quinn, L. Packer, *Free Radic. Biol. Med.* **9** (1990).
- H. Xie, X. Yang, Y. Cao, X. Long, H. Shang, Z. Jia, *CNS Neurosci. Ther.* **28** (2022).
- S. Yan, J. Lu, B. Chen, L. Yuan, L. Chen, L. Ju, W. Cai, J. Wu, *Antioxidants*. **13** (2024).
- T. Aiba, Y. Kono, T. Etoh, Y. Kawano, Y. Oshima, M. Inomata, *Cancer Sci.* **114** (2023).
- M. Attia, E.A. Essa, R.M. Zaki, A.A. Elkordy, *Antioxidants*. **9** (2020).
- I. V. Ozhogin, P. V. Zolotukhin, V. V. Tkachev, A.D. Pugachev, A.S. Kozlenko, A.A. Belanova, S.M. Aldoshin, B.S. Lukyanov, *Russ. Chem. Bull.* **70** (2021).
- D. Kaur, T. Behl, A. Sehgal, S. Singh, N. Sharma, S. Chigurupati, A. Alhowail, A. Abdeen, S.F. Ibrahim, C. Vargas-De-La-Cruz, M. Sachdeva, S. Bhatia, A. Al-Harrasi, S. Bungau, *Life Sci.* **284** (2021).
- D. Kong, A.A. Saqer, M. Carpinelli de Jesus, N. Khan, A. Jones, J.T. Blanchfield, M.T. Smith, C.M. Williams, *Bioorg. Med. Chem.* **69** (2022).
- A.C.F. Santos, R.C.S. Luz, F.S. Damos, A.E.G. Santana, D.G. Pessoa, M. Navarro, M.O.F. Goulart, *J. Solid State Electrochem.* **24** (2020).
- B.B. Petković, M. Ognjanović, B. Antić, V. Viktorovich Avdin, D.D. Manojlović, S. Vranješ Đurić, D.M. Stanković, *Electroanalysis*. **33** (2021).
- Y. Qian, L. Zhang, Y. Tian, *Anal. Chem.* **94** (2022).
- S. Lechner, R.R. Steimbach, L. Wang, M.L. Deline, Y.-C. Chang, T. Fromme, M. Klingenspor, P. Matthias, A.K. Miller, G. Médard, B. Kuster, *Nat. Commun.* **14** (2023).
- I.O. Levkovskiy, S. Mochizuki, A. Zheng, X. Zhang, F. Zhang, *Nano TransMed.* **2** (2023).
- Q. Yu, Z. Fang, S. Luan, L. Wang, H. Shi, *J. Mater. Chem. B.* **12** (2024).
- J. Gao, Q. Zhang, B. Wu, X. Gao, Z. Liu, H. Yang, J. Yuan, J. Huang, *Small*. **19** (2023).
- A. Ghosh, K. Kozłowski, T.W.J. Steele, *Polymers (Basel)*. **15** (2023).
- R.M. Annuur, D. Triana, T. Ernawati, Y. Murai, M. Aswad, M. Hashimoto, Z.P. Tachrim, *Molecules*. **29** (2024).
- D. Olender, M. Józkiwiak, H. Piotrowska-Kempisty, K. Sowa-Kasprzak, L. Zaprutko, I. Muszalska-Kolos, E. Baranowska-Wójcik, D. Szwajgier, *Pharmaceuticals*. **16** (2023).
- E. Popa, A.A. Andelesc, V. Badea, P. Svera (m. Ianăși), E.I. Szerb, *Molbank*. **2024** (2024).